Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.
days to go:
Expired
investment:
£103,672
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.
days to go:
Expired
investment:
£70,900
Symmetrical Power has developed an innovative solution that addresses the issue of energy wastage. After identifying the inefficiency of the 3 Phase Electrical Distribution Boards, Symmetrical Power is creating the ‘Intelligent Distribution Board’ (ID Board). It aims to prevent the challenge of peak demand whilst saving on energy bills. The working model of the product also received positive feedback from electrical specialists. Additionally, Symmetrical Power was also a Shell Springboard regional finalist (2018) for its new low-carbon ideas. With the proceeds, the company will complete design & begin distribution in Europe and to position itself as the go-to Distribution Board provider.
days to go:
Expired
investment:
£233,600
Wellbeing Sisters (WS) is a company that offers wellbeing advice, hosts an online shop, and sells a subscription box full of toxin-free health, beauty, and nutritional products by and for women. The company first launched its subscription box in 2019 for women trying to conceive. WS witnessed a sell-out of its series of one-off boxes tailored towards conceiving, pregnancy, early motherhood, midlife and menopause in 2020. WS aims to be a contender in the UK subscription box market that is set to be worth £1 billion by 2022. The company asserts that it has organically grown its social media following consisting of over 5,000 supporters. It will use the investment to invest in technology, product development, and marketing/PR.
days to go:
Expired
investment:
£153,394
Alyve provides personalised subscription nutrition powered by Artificial Intelligence (AI). It argues that 8.2 million UK vitamin users are looking for personalised nutrition in one capsule. Alyve asserts that its product can fulfil this demand. Users complete a 3-minute questionnaire where their responses are recorded by Alyve's intelligent algorithms. These then, based on the responses, help the user select one of Alyve's nutritional pills best matched to their goals and needs. Alyve then delivers the pills to the user's doorstep every 30 days. The company has recorded 4000+ questionnaires and completed 800+ orders in 25 countries since Q4 of 2020. It aims to become a contender in the $21 billion supplement market. The company will use the investment received to increase marketing efforts, transform Alyve into a household brand, introduce new product lines, increase staff, improve technology, and transform both digital and physical User Experiences (UX).
days to go:
Expired
investment:
£227,782
Solent Automation specialises in developing, deploying and supporting automation robots to perform and tackle common manual labour-intensive tasks in factories. To solve the 'pick-and-place' challenges in an industrial setup, these robots are created with proven reliable components coupled with proprietary software to solve 'pick-and-place' challenges in an industrial environment. Two of the company's noteworthy products are 'SOLPAL 8' and 'SOLPACK 1XP, both are equipped with an all-in-one gripping tool, and can handle 16 boxes per minute and 60 packs per minute, respectively. Backed by a team of experts from manufacturing and robotics, Solent Automation provides on-site installation, training, and remote support for its products. There is also a rent-to-buy option through a 3rd party finance company. With the investment, the company aims at providing more robotic equipment most needed in factories focused on labour-intensive work functions.
days to go:
Expired
investment:
£76,000
